Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …

A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to developing more efficient cancer detection methods and …

Despite decades of laboratory, epidemiological and clinical research, breast cancer
incidence continues to rise. Breast cancer remains the leading cancer-related cause of …

The etiopathogenesis of endometriosis is a multifactorial process resulting in a
heterogeneous disease. Considering that endometriosis etiology and pathogenesis are still …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …

Variants of uncertain significance fundamentally limit the clinical utility of genetic information.
The challenge they pose is epitomized by BRCA1, a tumour suppressor gene in which …

In vertebrate cells, the DNA damage response is controlled by three related kinases: ATM,
ATR, and DNA-PK. It has been 20 years since the cloning of ATR, the last of the three to be …

PARP inhibitors (PARPi), a cancer therapy targeting poly (ADP-ribose) polymerase, are the
first clinically approved drugs designed to exploit synthetic lethality, a genetic concept …

Mutations in BRCA1 and BRCA2 predispose individuals to certain cancers,–, and disease-
specific screening and preventative strategies have reduced cancer mortality in affected …